Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Verhagen M, Del Dotto P, van den Munckhof BS et al (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50:1323-1326
Amantadine treatment is an independent predictor of improved survival in Parkinson's disease
Uitti RJ, Rajput AH, Ahlskog JE et al (1996) Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46:1551-1556
Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Macmillan Health Care Information, Florham Park
Fahn S, Elton R, Members of UPDRS Development Committee (1987) In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease, vol. 2. Macmillan Health Care Information, Florham Park, pp 153-164
Anticholinergic drugs and amantadine in the treatment of Parkinson's disease
Calne DB (ed) Springer, Berlin Heidelberg New York
Lang AE, Blair RDG (1989) Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. In: Calne DB (ed) Drugs for the treatment of Parkinson's disease. Springer, Berlin Heidelberg New York, pp 307-323
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double blind, placebo-controlled study
Snow BJ, Macdonald L, Mcauley D et al (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double blind, placebo-controlled study. Clin Neuropharmacol 23:82-85
Regional variations in the phamacology of NMDA receptor channel blockers: Implications for therapeutic potential
Porter RHP, Greenamyre JT (1995) Regional variations in the phamacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64:614-623